01 Increasing adoption of precision-guided and smart munitions for modern warfare The global artillery ammunition market is witnessing a significant shift with the increasing adoption of precision-guided and smart munitions. Modern warfare demands greater accuracy, reduced collateral damage, and enhanced operational efficiency, driving militaries to invest in technologically advanced artillery systems that outperform traditional unguided shells.Smart munitions offer real-time targeting capabilities, programmable fuses, and improved lethality, which are valued in combat scenarios. As defense forces focus on precision and efficiency, the integration of these sophisticated ammunition types is expected to accelerate market growth, fostering innovation and reshaping strategies in artillery deployment.
02 Shift from conventional artillery to extended-range and high-impact systems Modern warfare is driving a transition in the artillery ammunition market from conventional shells to extended-range and high-impact systems. Armed forces are increasingly prioritizing superior reach, firepower, and battlefield effectiveness, leading to the adoption of advanced munitions capable of outperforming traditional artillery in both precision and impact.The demand for long-range and high-impact ammunition is projected to rise, fueled by evolving combat strategies and the need for rapid, accurate engagement. These advanced systems enhance operational flexibility and destructive capability, allowing militaries to address contemporary threats while strengthening strategic advantage worldwide.
March 2026 Amgen expanded its cardiovascular medicine portfolio through continued development and commercialization initiatives focused on innovative therapies for cardiovascular disease management, including conditions associated with angina risk.
September 2025 Bayer advanced its cardiovascular drug pipeline through clinical and commercialization initiatives targeting heart-related conditions, strengthening its presence in cardiovascular therapeutics.
May 2025 Sanofi expanded its cardiovascular care portfolio through strategic initiatives focused on improving treatment options for patients with chronic cardiovascular conditions.